Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
SCLC: early-phase trial registry
6 of 11 indexed SCLC trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 6 currently recruiting · #1,577 of 28,707 conditions by registered trial count
SCLC: 11 US clinical trials tracked, 6 recruiting.
SCLC is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition sclc
OPEN 6 | RECR 55% | LATE 0 | EARLY 9 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)
SCLC lists 6 open slots (55% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for SCLC on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
SCLC is recruiting above its size-band peers.
6 of 11 indexed trials (54.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates SCLC research.
National Cancer Institute (NCI) accounts for 2 of 11 trials (18.2%). 10 distinct sponsors appear on at least one study for this condition label.
-
Typical SCLC enrolment sits around 120 participants.
Median target enrolment is 120 among the 11 trials that report a genuine target (sentinel values excluded). 4 of those (36.4%) plan for fewer than 100 participants.
-
SCLC research is mostly interventional.
11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis
NCT06657222
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
Wake Forest University Health Sciences
NCT05703269
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
National Cancer Institute (NCI)
NCT04826341
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Zai Lab (Shanghai) Co.
NCT06179069
SLV-154 Treatment of Metastatic Solid Tumors
Solve Therapeutics
NCT06771219
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Y-mAbs Therapeutics
NCT05130255
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
NCT07145333
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
AstraZeneca
NCT02734004
Study of Oral MRT-2359 in Selected Cancer Patients
Monte Rosa Therapeutics
NCT05546268
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
National Cancer Institute (NCI)
NCT04802174
Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01797159
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on SCLC records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on SCLC trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this SCLC page
11 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 SCLC trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most SCLC trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This SCLC condition card totals 11 registered trials; most-linked intervention Berzosertib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.